3 results on '"Mu-N Liu"'
Search Results
2. Interleukin-1 family and serotonin transporter in first-episode, drug-naive major depressive disorder: A pilot study
- Author
-
Kai Chun Yang, Ying-Jay Liou, Bang Hung Yang, Yuan-Hwa Chou, Mu-N Liu, and Li-Yu Hu
- Subjects
medicine.medical_specialty ,medicine.drug_class ,Thalamus ,Pilot Projects ,Serotonergic ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,mental disorders ,medicine ,Humans ,Biological Psychiatry ,Serotonin transporter ,Serotonin Plasma Membrane Transport Proteins ,First episode ,Depressive Disorder, Major ,biology ,business.industry ,Putamen ,Receptor antagonist ,medicine.disease ,030227 psychiatry ,Psychiatry and Mental health ,Drug-naïve ,Endocrinology ,Pharmaceutical Preparations ,biology.protein ,Major depressive disorder ,business ,030217 neurology & neurosurgery ,Interleukin-1 ,medicine.drug - Abstract
Abnormalities of neuroinflammatory process and serotonergic system have been reported in major depressive disorder (MDD). However, most previous studies were performed in recurrent MDD and only a few studies explored the interaction of the two systems. This study examined both systems concurrently and their clinical relevance in first-episode drug-naive MDD. Thirty-four MDD patients and 34 age and gender matched healthy controls (HC) were recruited. Plasma concentrations of the cytokines of interleukin-1 (IL-1) family, including IL-1α, IL-1β, IL-1 receptor antagonist (IL-1Ra) and IL-1 receptor type 2 (IL-1R2) were measured using enzyme-linked immune-sorbent assays. The serotonin transporter (SERT) availability in midbrain, thalamus, caudate, and putamen was examined by single-photon emission computed tomography with 123I-ADAM. There were significantly lower concentrations of pro-inflammatory IL-1β and its inhibitor, IL-1R2 in MDD than HC. The SERT availability was at the same level between groups. A negative association between IL-1Ra concentration and the SERT availability in midbrain was observed in MDD but not in HC. Both IL-1β concentration and the SERT availability in caudate negatively correlated with depression severity and the effect of IL-1β was not moderated or mediated by the SERT. In conclusion, this study demonstrated the involvement of IL-1 family in the early stage of MDD, especially for IL-1β. SERT was not the main central target of altered IL-1β and these two systems might contribute to MDD by different mechanisms. The pathophysiology might be varied between early and recurrent MDD and tuning treatment strategies at different clinical stages might be needed.
- Published
- 2021
- Full Text
- View/download PDF
3. Transdiagnostic and Illness-Specific Functional Dysconnectivity Across Schizophrenia, Bipolar Disorder and Major Depression and Relationships with Working Memory
- Author
-
Lena Palaniyappan, Chu Chung Huang, Shih-Jen Tsai, Chun-Yi Zac Lo, Chia Chun Hung, Qiang Luo, Mu-N Liu, Ching Po Lin, Trevor W. Robbins, Kun Hsien Chou, Jianfeng Feng, M Deanna, and Albert C. Yang
- Subjects
medicine.medical_specialty ,Informed consent ,Working memory ,Schizophrenia ,medicine ,Major depressive disorder ,Cognition ,Bipolar disorder ,Institutional review board ,medicine.disease ,Psychiatry ,Psychology ,Neurocognitive - Abstract
Background: Mental disorders are typically defined as distinct diagnostic entities but similar patterns of clinical impairments are frequently found in practice across the diagnostic groups. We investigate whether the transdiagnostic deficits result from a common neurocognitive mechanism across disorders, or various illness-specific mechanisms, or a combination of both. Methods: Functional MRI data were collected from the clinically stable patients with major depressive disorder (MDD; n=53), bipolar disorder (BIP; n=78), or schizophrenia (SCZ; n=100), and the matched healthy control subjects (n=109) using a single scanner. Group comparisons were conducted to identify both the transdiagnostic and the illness-specific features. A multivariate approach with cross-validation was used to assess the association between the brain functional dysconnectivity and the cognitive deficits. The confounding effect of medication on the findings was also tested. Findings: Compared with the healthy controls, the patients displayed shared working memory deficits [Cohen's d (d) in MDD/BIP/SCZ=0·73/0·65/0·89], and functional dysconnectivity within brain networks [somatomotor (d:0·50- 0·58) and salience (d:0·52-0·58)] and between brain networks [subcortical-limbic (d:0·55-0·69) and subcortical-dorsal attention (d:0·56-0·61)]. The illness-specific dysconnectivity were found between the executive control and default-mode networks in SCZ (d:0·46-0·56), between the salience and subcortical networks in BIP (d:0·47-0·48), and between the salience and default-mode networks in MDD (d:0·53-0·55). Working memory deficits were associated with a linear combination of 10 transdiagnostic and 4 illness-specific dysconnectivity patterns (r = 0·368, p = 2·45e-12, n = 340). The associations between the dysconnectivity patterns and the medication dosage did not reach statistical significance. Interpretation This study emphasizes that transdiagnostic deficits in cognition may be mediated by multiple interactions between many brain networks, and including diagnostic-specific patterns of functional dysconnectivity in different psychiatric disorders. Funding Statement: Ministry of Science and Technology, National Health Research Institutes (Taiwan). National Natural Science Foundation, National Key Research and Development Program, Shanghai Municipal Science and Technology Major Project, Shanghai Science and Technology Innovation Plan, Shanghai AI Platform for Diagnosis and Treatment of Brain Diseases, the Project of Zhangjiang Hi-Tech District Management, and Zhangjiang Lab (China). Academic Medical Organsiation of Southwest Ontario and the Bucke Family Funds. Declaration of Interests: Dr Palaniyappan reports educational grants and personal fees from Otsuka Canada and Janssen Canada, educational grants from Sunovion, personal fees from SPMM Course (UK) and Canadian Psychiatric Association, and royalties from Oxford University Press outside the submitted work. Dr. Robbins reports personal fees from Cambridge Cognition, Unilever, Mundipharma, Greenfiled Inc, grants from Shionogi, Lundbeck, Small Pharma, personal fees from Elsevier, Springer Verlag, outside the submitted work. No other disclosures were reported Ethics Approval Statement: The study was approved by the Institutional Review Board of Taipei Veterans General Hospital. Written informed consent was obtained from all participants before commencement of the study.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.